9MW3011

DRUG3 trials

Sponsors

Mabwell (Shanghai) Bioscience Co., Ltd.

Conditions

Beta-ThalassemiaHealthyPolycythemia Vera

Phase 1

Single Ascending Dose Study of 9MW3011 in Chinese Healthy Subject

CompletedNCT06389942

Mabwell (Shanghai) Bioscience Co., Ltd.Healthy

Start: 2023-03-10End: 2024-05-31Updated: 2024-12-27

A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera

RecruitingNCT06752746

Mabwell (Shanghai) Bioscience Co., Ltd.Polycythemia Vera

Start: 2024-03-21End: 2026-06-30Target: 108Updated: 2025-05-11

A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia

RecruitingNCT06772766

Mabwell (Shanghai) Bioscience Co., Ltd.Beta-Thalassemia

Start: 2024-12-30End: 2026-10-31Target: 40Updated: 2025-01-14